FEATURED COMPANIES
- Alkermes, PLC.
- Camurus AB
- Hikma Pharmaceuticals PLC
- Indivior PLC
- Mallinckrodt Co.
- Masimo Corp.
Global Opioid Use Disorder Market Size, Share & Trends Analysis Report, by Drug (Methadone, Buprenorphine {Bunavil, Suboxone, Zubsclv, Buprenorphine} Naltrexone) and Forecast 2019-2025.
The global opioid use disorder market is estimated to grow at a significant CAGR during the forecast period. High side effects of opioids and the rising frequency of OUD patients are the major factors that are driving the global opioid market. As per the American Psychiatric Association, In 2017, in the US, over 31,000 people died from an opioid overdose, both prescribed and non-prescribed, among them over 16,000 people died from the overdose of heroin and 15,000 people died from the overdose of prescribes opioids. Counseling, opioid replacement therapy, and gradual discontinuation of opioids are some of the non-medication therapies that are used to prevent OUD.
The global opioid use disorder market is segmented based on Drug type. Based on drug type, the market is segmented into Methadone, Buprenorphine, and Naltrexone. And Buprenorphine is segmented into Bunavil, Suboxone, Zubsclv, Sublocade, and Others. Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW. North America has witnessed significant share owing to the availability of government policies for the misuse of drugs and awareness among people. For instance, in October 2017, in the US, in the Center for Disease Control and Prevention (CDC) launched the Rx Awareness campaign, to aware the public about side effects of the overdose of opioids.
The major players providing opioid use disorder (OUD) drugs include Indivior PLC, BioDelivery Sciences International, Inc., Alkermes, PLC, Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corp, Camurus AB, Hikma Pharmaceuticals PLC, and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in November 2017, Alkermes, Inc. launched OUD drug VIVITROL, it was funded by the National Institute on Drug Abuse (NIDA), and it is the injectable and only once-monthly formulation.
Research Methodology
The market study of the global opioid use disorder market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.
Secondary Sources Include:
Market Segmentation:
The global opioid use disorder market is estimated to grow at a significant CAGR during the forecast period. High side effects of opioids and the rising frequency of OUD patients are the major factors that are driving the global opioid market. As per the American Psychiatric Association, In 2017, in the US, over 31,000 people died from an opioid overdose, both prescribed and non-prescribed, among them over 16,000 people died from the overdose of heroin and 15,000 people died from the overdose of prescribes opioids. Counseling, opioid replacement therapy, and gradual discontinuation of opioids are some of the non-medication therapies that are used to prevent OUD.
The global opioid use disorder market is segmented based on Drug type. Based on drug type, the market is segmented into Methadone, Buprenorphine, and Naltrexone. And Buprenorphine is segmented into Bunavil, Suboxone, Zubsclv, Sublocade, and Others. Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW. North America has witnessed significant share owing to the availability of government policies for the misuse of drugs and awareness among people. For instance, in October 2017, in the US, in the Center for Disease Control and Prevention (CDC) launched the Rx Awareness campaign, to aware the public about side effects of the overdose of opioids.
The major players providing opioid use disorder (OUD) drugs include Indivior PLC, BioDelivery Sciences International, Inc., Alkermes, PLC, Orexo US, Inc., Titan Pharmaceuticals, Inc., Omeros Corp, Camurus AB, Hikma Pharmaceuticals PLC, and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in November 2017, Alkermes, Inc. launched OUD drug VIVITROL, it was funded by the National Institute on Drug Abuse (NIDA), and it is the injectable and only once-monthly formulation.
Research Methodology
The market study of the global opioid use disorder market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.
Secondary Sources Include:
- Reports of companies involved in the market
- Authentic Public Databases
- Whitepapers such as research papers and news blogs
- Company websites and their product catalog
Market Segmentation:
- Global Opioid Use Disorder Market Research and Analysis by Drug Type
- Comprehensive research methodology of the global opioid use disorder market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Insights about market determinants which are stimulating the global opioid use disorder market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Alkermes, PLC.
- Camurus AB
- Hikma Pharmaceuticals PLC
- Indivior PLC
- Mallinckrodt Co.
- Masimo Corp.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusions
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Alkermes, PLC
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. BioDelivery Sciences International, Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Titan Pharmaceuticals, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Orexo US, Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Hikma Pharmaceuticals PLC
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Global Opioid Use Disorder Market by Segmentation
5.1. By Treatment
5.1.1. Methadone
5.1.2. Buprenorphine
5.1.2.1. Bunavil
5.1.2.2. Suboxone
5.1.2.3. Zubsclv
5.1.2.4. Sublocade
5.1.2.5. Others
5.1.3. Naltrexone
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Alkermes, PLC.
7.2. BioDelivery Sciences International, Inc.
7.3. Camurus AB
7.4. Hikma Pharmaceuticals PLC
7.5. Indivior PLC
7.6. Mallinckrodt Co.
7.7. Masimo Corp.
7.8. MediciNova, Inc.
7.9. Mylan N.V.
7.10. Novartis AG
7.11. Omeros Corp.
7.12. Orexo US, Inc.
7.13. Teva Pharmaceuticals Industrial, Ltd.
7.14. Titan Pharmaceuticals, Inc.
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusions
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Alkermes, PLC
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. BioDelivery Sciences International, Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Titan Pharmaceuticals, Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Orexo US, Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Hikma Pharmaceuticals PLC
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Global Opioid Use Disorder Market by Segmentation
5.1. By Treatment
5.1.1. Methadone
5.1.2. Buprenorphine
5.1.2.1. Bunavil
5.1.2.2. Suboxone
5.1.2.3. Zubsclv
5.1.2.4. Sublocade
5.1.2.5. Others
5.1.3. Naltrexone
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Alkermes, PLC.
7.2. BioDelivery Sciences International, Inc.
7.3. Camurus AB
7.4. Hikma Pharmaceuticals PLC
7.5. Indivior PLC
7.6. Mallinckrodt Co.
7.7. Masimo Corp.
7.8. MediciNova, Inc.
7.9. Mylan N.V.
7.10. Novartis AG
7.11. Omeros Corp.
7.12. Orexo US, Inc.
7.13. Teva Pharmaceuticals Industrial, Ltd.
7.14. Titan Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
- Alkermes, PLC.
- BioDelivery Sciences International, Inc.
- Camurus AB
- Hikma Pharmaceuticals PLC
- Indivior PLC
- Mallinckrodt Co.
- Masimo Corp.
- MediciNova, Inc.
- Mylan N.V.
- Novartis AG
- Omeros Corp.
- Orexo US, Inc.
- Teva Pharmaceuticals Industrial, Ltd.
- Titan Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
